Hologic, Inc. (NASDAQ:HOLX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have been given a consensus rating of “Moderate Buy” by the thirteen analysts that are presently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $87.50.

HOLX has been the subject of several recent research reports. Evercore ISI lifted their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Leerink Partners lowered their price target on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, October 15th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th.

Hologic Price Performance

Shares of Hologic stock opened at $82.33 on Friday. The stock has a 50 day moving average of $80.99 and a 200 day moving average of $77.98. Hologic has a 12 month low of $66.53 and a 12 month high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The firm has a market cap of $19.12 billion, a PE ratio of 28.00, a PEG ratio of 2.94 and a beta of 0.98.

Insiders Place Their Bets

In other news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.75% of the company’s stock.

Hedge Funds Weigh In On Hologic

A number of large investors have recently bought and sold shares of the business. Assetmark Inc. increased its holdings in shares of Hologic by 27.5% in the 3rd quarter. Assetmark Inc. now owns 6,667 shares of the medical equipment provider’s stock valued at $543,000 after acquiring an additional 1,437 shares during the period. Equitable Trust Co. bought a new position in Hologic in the third quarter worth about $252,000. Principal Financial Group Inc. lifted its position in shares of Hologic by 3.6% during the third quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider’s stock valued at $21,957,000 after buying an additional 9,419 shares during the last quarter. Financial Security Advisor Inc. bought a new stake in shares of Hologic in the 3rd quarter valued at about $202,000. Finally, Moloney Securities Asset Management LLC grew its position in shares of Hologic by 3.8% in the 3rd quarter. Moloney Securities Asset Management LLC now owns 12,839 shares of the medical equipment provider’s stock worth $1,046,000 after buying an additional 469 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.